How effective are our COVID-19 booster vaccines as new variants emerge?

Publicly released:
Australia; NSW; VIC
Photo by Markus Spiske on Unsplash
Photo by Markus Spiske on Unsplash

Original COVID-19 vaccines - and to a potentially larger degree bivalent vaccines - still function well as boosters to prevent waning immunity to COVID-19, according to Australian researchers. The team compiled evidence from 14 peer-reviewed papers, pre-prints and press releases from vaccine manufacturers to analyse the data on how the antibody response differs between vaccines targeting the ancestral COVID-19 strain to newer ones targeting specific variants. Using a model that estimates how antibody response levels translate to vaccine effectiveness, the researchers say continuing to boost with the original vaccines can still enhance protection against both symptoms and severe COVID-19 and variant-modified vaccines may provide additional protection even if they come up against a different variant to the one they are designed to target.

Media release

From:

New research shows variant-specific vaccines offer better protection against COVID-19

The analysis by the Kirby institute at UNSW Sydney provides crucial information on the effectiveness of updated COVID-19 boosters, and has been cited in Australian and global statements on vaccine rollout.

New research published today in Nature Medicine, shows that newer variant-specific bivalent vaccines offer on average 1.6 times better immunity against COVID-19 than the original, single-strain ‘ancestral’ vaccines.

"We’re in an incredible position now where we have high availability of a number of different COVID-19 vaccines. But with this comes questions around which vaccines policy bodies should recommend, and which ones countries should purchase.” says the study’s lead author, Dr Deborah Cromer. “We’ve crunched the numbers and found that getting boosted with any of the available vaccines will provide significant protection against COVID-19, although a variant-specific booster provides marginally higher protection.”

This is the first analysis globally to aggregate data from the available clinical studies that have administered booster vaccination with both ancestral-based vaccines and variant-modified vaccines. The Kirby Institute researchers, in collaboration with colleagues from the Doherty Institute, collated the available data, and then used it to conduct an analysis that predicted the relative effectiveness of these booster vaccines.

“If we assume that we are in a position where around people in the population have around 50% protection from COVID-19 disease, then this protection can be boosted extremely well – up to 86% - by the ancestral vaccines. But when the option is available, boosting with a variant-specific vaccine can increase protection in the population up to 91%. Any improvement in protection may be important for people at higher risk of serious infection or hospitalisation, such as the elderly and immunocompromised,” says Dr Cromer.

An earlier version of this analysis was published as a pre-print in November last year and has been cited in vaccination statements from the Australian Technical Advisory Group on Immunisation (ATAGI) and World Health Organization.

“As we move into this next phase of the pandemic, it is important that the population as a whole remains well protected to reduce the spread of COVID-19, especially for those in our community who are most vulnerable. Our analysis provides evidence that boosting with any vaccine is an effective way to protect against COVID-19, although variant-specific vaccines offer slightly better protection.”

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research Springer Nature, Web page The URL will go live after the embargo ends
Journal/
conference:
Nature Medicine
Research:Paper
Organisation/s: Kirby Institute, UNSW Sydney, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Monash University
Funder: This work was supported by Australian NHMRC program grant 1149990 to S.J.K. and M.P.D.; Australian MRFF award 2005544 to S.J.K. and M.P.D.; and MRFF 2015313 to M.P.D. D.C., K.S., M.P.D. and S.J.K. are supported by NHMRC fellowships (numbers 1173528, 1177174, 1173027 and 1136452, respectively). The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health.
Media Contact/s
Contact details are only visible to registered journalists.